Document Classification

Section Type: METHODS

Text: In this open-label, randomised, phase 3 trial, we randomly assigned patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and WHO performance status 0-2 to receive either first-line treatment with bolus (400 mg/m (2)) and infusional (2400 mg/m (2)) fluorouracil plus leucovorin (400 mg/m (2)) (simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m (2)) (FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m (2)) (FOLFIRI) or first-line FOLFOX6 and second-line FOLFIRI.